FOX Translator
No data currently available.
No data currently available.
In the wide and varied family of the thousands and thousands of funds out there, the exchange-traded fund is one of the more consumer-friendly ones.
Unlike mutual funds, exchange-traded funds, or ETFs, behave more like stocks. You can buy
into an ETF at any time, and sell it whenever you feel like it. And like a stock, an ETF's value can rise and fall--depending
on what the ETF is invested in.What do ETFs invest in? Well, they're typically linked to an index like the Dow Jones Industrial
Average or the S&P 500. So, if you had an ETF that trades the same companies that make up the Dow or the S&P, it will
rise and fall in value pretty much the same amount as the Dow or S&P.
You can also buy ETFs that invest in other
types of products, like bonds, currencies, gold or other commodities. The ETF market has grown considerably in the past few
years, so there is no shortage of ETFs to invest in.
Home / Markets / Industries / Health Care
Monday, June 16, 2008
Metabasis to Present at the Jefferies 2nd Annual Healthcare Conference
Comtex
SAN DIEGO, Jun 16, 2008 (BUSINESS WIRE) ----Metabasis Therapeutics (Nasdaq: MBRX), announced today that Dr. Paul Laikind, president and chief executive officer, will present at the Jefferies 2nd Annual Healthcare Conference in New York, NY. Dr. Laikind is scheduled to present on Thursday, June 26 at 11:45 a.m. Eastern Time and is expected to provide an overview of the Company and its product candidates. The Company's presentation will be webcast.
To access the live broadcast and the subsequent archived recording and of the presentation, please log onto the Company's website at www.mbasis.com under the "Investors" section. The audio recordings will be archived there for 30 days following the live presentation. Please connect to Metabasis' website several minutes prior to the start of the presentation to ensure adequate time for any software download that may be necessary.
About Metabasis (www.mbasis.com):
Metabasis is a biopharmaceutical company using its proprietary technologies, scientific expertise and unique capabilities for targeting the liver and liver pathways. The Company has established a broad pipeline of product candidates and advanced research programs targeting large markets with significant unmet needs. Metabasis' core area of focus is on the discovery and development of drug candidates to treat metabolic diseases such as hyperlipidemia and diabetes, among others. Although not a core focus of the Company, Metabasis has also discovered and developed drug candidates indicated for the treatment of liver diseases such as hepatitis and primary liver cancer, which it now intends to license or partner. All product candidates were developed internally using proprietary technologies.
SOURCE: Metabasis Therapeutics, Inc.
Metabasis Therapeutics, Inc. Constance Bienfait, Vice President Investor Relations & Corporate Communications 858-622-5575
Copyright Business Wire 2008 ********************************************************************** As of Thursday, 06-12-2008 23:59, the latest Comtex SmarTrend� Alert, an automated pattern recognition system, indicated an UPTREND on 04-30-2008 for MBRX @ $2.68. For more information on SmarTrend, contact your market data provider or go to www.mysmartrend.com SmarTrend is a registered trademark of Comtex News Network, Inc. Copyright � 2004-2008 Comtex News Network, Inc. All rights reserved.
Market Snapshot
| Symbol | Last Price | Netchange | Volume |
|---|---|---|---|
| -- | -- | -- | -- |
| -- | -- | -- | -- |
| -- | -- | -- | -- |
| -- | -- | -- | -- |
| -- | -- | -- | -- |
